1Bartsch C, Bartsch H, Fuchs U et al. Stage-dependent depression of melatonin in patients with primary breast cancer. Correlation With prolactin, thyroid stimulating hormone, and steroid receptors.Cancer, 1989;64(2) :426～33
2Bartsch C, Bartsch H, Bellmann O et al. Depression of serum melatonin in patients with primary breast cancer is not due to an increased peripheral metabolism. Cancer, 1991 ;67(6): 1681～4
3Holdaway IM, Aason BH, Gibbs EE et al. Seasonal changes in serum melatonin in women with previous breast cancer. Br J Can cer, 1991;64(1):149～53
4Crespo D, Fernandez-Viadero C, Verduga R et al. Interaction between melatonin and estradiol on morphological and morphometric features of MCF-7 human breast cancer cells. J Pineal Res, 1994;16(4) :215～22
5Cos S, Blask DE. Melatonin modulates growth factor activity in MCF-7 human breast cancer cells. J Pineal Res, 1994; 17 (1): 25～32
6Lissoni P, Paolorossi F, Meregalli S et al. Melatonin as Modulator of cancer endocrine therapy. In: Proceedings of 2nd Locamo Meet ing on neuroendocrinoimmunity. Switzerland, 1996: 27
7Lissoni P, Barni S, Cazzaniga M et al. Efficacy of the concomitant administration of the pineal hormone melatonin in cancer im munotherapy with low-dose IL-2 in patients with advanced solid tu mots who had progressed on IL-2 alone. Oncology, 1994; 51 (4):344～7
8Shellard SA, Whelan RD, Hill BT. Growth inhibitory and cytotoxic effects of melatonin and its metabolites on human tumour cell lines in vitro. Br J Ca ncer, 1989; 60 (3): 288～90
9Neri B, Fiorelli C, Moroni F et al. Modulation of human lymphoblastoid interferon activity by melatonin in metastatic renal cell carcinoma. A phase Ⅱ study Cancer, 1994;73(12):3015～9
10Lissoni P, Bami S, Tancini G et al. A study of the mechanisms involved in the immunostimulatory action of the pineal hormone in cancer patients. Oncology, 1993;50(6):399～402
